CENTOGENE
THE RARE DISEASE COMPANY

آزمایشگاه دنا
DeNA Laboratory

CentoCancer®

STRIVE FOR THE MOST COMPLETE INFORMATION

CentoCancer® – our most complete Oncogenetics panel for hereditary mutations

Certain hereditary pathogenic variants confer an increased risk of developing cancers during an individual's lifetime. The early identification of pathogenic variants in cancer predisposition genes represents a fundamental step in the diagnosis, management and treatment of individuals and families with hereditary cancer syndromes.

PANEL COMPOSITION

CentoCancer®, our most comprehensive cancer panel has now been extended to 56 genes, offering you complete answers to help you choose the best possible therapeutic approach for your patients. Each gene in CentoCancer® has been carefully selected based on its risk potential in the development of one or more of the following cancers:

- Breast
- Ovarian
- Colorectal
- Gastric
- Bowel
- Endometrial
- Pancreatic
- Melanoma
- Renal
- Prostate

WHO SHOULD CONSIDER CentoCancer® FOR GENETIC TESTING?

CentoCancer® is appropriate for:

- Individuals with a positive personal history of early-onset cancer, rare cancer, bilateral cancer, or multiple primary cancers
- Unaffected individuals with a positive family history of multiple generations of cancers, rare cancers or early-onset cancers
- Individuals in whom the suspected genetic diagnoses are not covered by a single targeted panel or if a targeted panel testing was previously negative

CentoCancer® – Panel composition and methodology

CentoCancer® includes the following 56 most relevant cancer associated genes:

APC	CDH1	HNF1B	MSH2	POLD1	RAD51D	STK11
ATM	CDK4	HOXB13	MSH6	POLE	RET	TP53
BARD1	CDKN2A	MC1R	MUTYH	POT1	SDHA	TSC1
BLM	CHEK2	MEN1	NBN	PRSS1	SDHAF2	TSC2
BMPR1A	EPCAM	MET	NTHL1	PTCH1	SDHB	VHL
BRCA1	FH	MITF	PALB2	PTEN	SDHC	WT1
BRCA2	FLCN	MLH1	PMS1	RAD50	SDHD	XRCC2
BRIP1	HNF1A	MRE11A	PMS2	RAD51C	SMAD4	XRCC3

KEY PANEL FACTS

- NGS bidirectional sequencing of all 56 genes in the panel, including coding regions (all exons) and exon/intron boundaries +/-10bp
- Coverage: >99% of target bases covered at >20x; mean coverage ≥180x
- 100% coverage of core genes: BRCA1, BRCA2, TP53
- CNV analysis from NGS data included for all genes
- All reported variants confirmed by Sanger sequencing or MLPA/qPCR
- All relevant deep intronic mutations described in HGMD® 2017.3 and CentoMD® included
- Turnaround Time: 10 business days
- Required Material: ≥4µg DNA or ≥1ml EDTA blood or ≥1 filter card

Some common cancer predisposition syndromes covered by CentoCancer®

Syndromes	Associated cancers
HEREDITARY BREAST/OVARIAN CANCER BRCA1, BRCA2	Breast, ovarian, prostate, pancreatic, melanoma
LI-FRAUMENI SYNDROME TP53	Breast, sarcomas, adrenocortical carcinoma, leukemia, brain tumors
COWDEN SYNDROME PTEN	Breast, thyroid, benign lesions of skin, hamartoma, renal cell carcinoma, uterine
HNPCC (LYNCH SYNDROME) MLH1, MSH2, MSH6, PMS1, PMS2	Colorectal (often right sided and multifocal), endometrial, ovarian, small bowel, stomach, pancreas, ureter, renal pelvis
FAMILIAL ADENOMATOUS POLYPOSIS APC	Polyposis, colorectal, thyroid, gastric, periampullary carcinoma, hepatoblastoma
VON HIPPEL-LINDAU VHL	Renal cell carcinoma, retinal angioma, cerebellar hemangioblastoma, pheochromocytoma, pancreatic cysts, islet cell tumor
MULTIPLE ENDOCRINE NEOPLASIA MEN1, RET	Parathyroid tumors, pancreatic tumors, pituitary tumors, medullary thyroid cancer, pheochromocytoma, neuromas
RETINOBLASTOMA RB1	Retinoblastoma, often bilateral and <1 year of age, also associated increased risk of soft tissue sarcomas, melanoma, brain tumors

HEREDITARY CANCER AND/OR SUSCEPTIBILITY

Selection of genetic test/panel according to family history and clinical data

BRCA1, BRCA2 panel	BRCA1, BRCA2
Breast ovarian cancer panel	CDH1, PTEN, STK11, TP53
Breast ovarian cancer panel PLUS	ATM, BARD1, BRIP1, CHEK2, NBN1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, RAD50, RAD51C, RAD51D, XRCC2
CentoBreast® panel	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, RAD51C, STK11, TP53
Colon cancer with polyps panel	APC, BMPR1A, MUTYH, PTEN, SMAD4, STK11
Colon cancer non-polyposis panel	EPCAM, MSH2, MLH1, MSH6, PMS2
CentoColon extended panel	APC, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53
Gastric cancer panel, targeted	BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS1, PMS2, SMAD4
Ovarian cancer panel, targeted	BARD1, BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MRE11A, MSH2, MSH6, NBN, PMS1, PMS2, RAD50, RAD51C, RAD51D, STK11, TP53
Prostate cancer panel	BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, NBN, PTEN, TP53
Pancreatic cancer panel, targeted	APC, ATM, BMPR1A, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS1, PMS2, PRSS1, SMAD4, STK11
Renal cancer panel, targeted	EPCAM, FH, FLCN, HNF1A, HNF1B, MET, MITF, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN, SDHB,
Skin cancer panel, targeted	CDKN2A, EPCAM, MC1R, MITF, MLH1, MSH2, MSH6, PMS1, PMS2, POT1, PTCH1, XRCC3
Thyroid cancer panel, targeted	APC, PTEN, RET
Uterine cancer panel, targeted	EPCAM, MLH1, MSH2, MSH6, PMS1, PMS2, PTEN
PGL / PCC / GIST panel, targeted	GDNF, NF1B, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, TP53, VHL
Multiple endocrine neoplasias / paraganglioma/pheochromocytoma panel	CDKN1B, MAX, MEN1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL

Identification of specific cancer-causing pathogenic variant

Genetic counseling, genetic testing of all family members with consent

No pathogenic variants identified

Complex family history, variability of cancers and absence of known genetic cause in the family

CentoCancer® panel	APC, ATM, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FH, FLCN, HNF1A, HNF1B, HOXB13, MC1R, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NTHL1, PALB2, PMS1, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3

Identification of specific cancer-causing pathogenic variant

No pathogenic variant identified

WES analysis

Identification of specific cancer-causing pathogenic variants

Genetic counseling, genetic testing of all family members with consent

آزمایشگاه
دنا
DeNA Laboratory

www.DNA-Lab.ir

Contact details:

No. 4, Niloo St., Vali-Asr Ave.
Tehran, Iran

تهران، خیابان ولیعصر، بالاتر از بیمارستان دی،
نرسیده به پل همت، سمت چپ، خیابان نیلو،
نبش بن بست دوم

Info@DNA-Lab.ir
Phone: (+98 21) 43936
Fax: (+98 21) 89770011

ISO 9001:2008
TÜV NORD

www.CENTOGENE.com

Contact details:

CENTOGENE AG
Schillingallee 68
18057 Rostock
Germany

Email: dmqc@centogene.com
Phone: +49 (0)381 203 652 - 222
Fax: +49 (0)381 203 652 - 119

CLIA #99D2049715
ISO 15189:2012

15189SM
cap
ACCREDITED
ISO 15189:2007

CAP
ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

EMQN